Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018
Cited by 568 works. doi:10.1016/s1470-2045(18)30144-x Open-access PDF
Authors
- Marina Chiara Garassino
- Byoung Chul Cho
- Joo-Hang Kim
- Julien Mazières
- Johan Vansteenkiste
- H. Léna
- Jesus Corral Jaime
- John D. Powderly
- CHRISTOS CHOUAID
- Paolo Bidoli
- Paul Wheatley‐Price
- Keunchil Park
- Ross Andrew Soo
- Yifan Huang
- Catherine Wadsworth
- Phillip A. Dennis
- Naiyer A. Rizvi
- Luis Paz-Ares Rodríguez
- Silvia Novello
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Immune Checkpoint Blockade in Cancer Therapy
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up